Literature DB >> 24512575

Pediatric migraine: abortive management in the emergency department.

David C Sheridan1, David M Spiro, Garth D Meckler.   

Abstract

Studies suggest that headache accounts for approximately 1% of pediatric emergency department (ED) visits. ED physicians must distinguish between primary headaches, such as a tension or migraine, and secondary headaches caused by systemic disease including neoplasm, infection, or intracranial hemorrhage. A recent study found that 40% of children presenting to the ED with headache were diagnosed with a primary headache, and 75% of these were migraine. Once the diagnosis of migraine has been made, the ED physician is faced with the challenge of determining appropriate abortive treatment. This review summarizes the most recent literature on pediatric migraine with an emphasis on diagnosis and abortive treatment in the ED.
© 2013 American Headache Society.

Entities:  

Keywords:  abortive; emergency department; migraine; pediatric

Mesh:

Substances:

Year:  2013        PMID: 24512575     DOI: 10.1111/head.12253

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  4 in total

1.  Intranasal sumatriptan for migraine in children.

Authors:  Ran D Goldman; Garth D Meckler
Journal:  Can Fam Physician       Date:  2015-05       Impact factor: 3.275

Review 2.  Diagnosis and Treatment of Childhood Migraine.

Authors:  Kelsey Merison; Howard Jacobs
Journal:  Curr Treat Options Neurol       Date:  2016-11       Impact factor: 3.598

Review 3.  Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update.

Authors:  János Tajti; Délia Szok; Anett Csáti; László Vécsei
Journal:  Curr Pain Headache Rep       Date:  2016-01

4.  A randomized controlled pilot study of intranasal lidocaine in acute management of paediatric migraine and migraine-like headache.

Authors:  Kate Maki; Quynh Doan; Kendra Sih; Karly Stillwell; Alaina Chun; Garth Meckler
Journal:  Paediatr Child Health       Date:  2022-06-23       Impact factor: 2.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.